Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study

6533b860fe1ef96bd12c3a99

RESEARCH PRODUCT

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study

Matthias Schmitz Suna Su Aksay Alexander Sartorius Maren Leifheit-nestler Inga Zerr Laura Bindila Markus J. Schwarz Natalie Moll Dieter Haffner Carolin Hoyer Christoph Janke Beat Lutz Laura Kranaster Henrik Zetterberg Cagakan Ozbalci Cagakan Ozbalci J. Malte Bumb Manfred Thiel Peter Zill Kaj Blennow Kaj Blennow Norbert Müller

subject

Male Oncology medicine.medical_treatment chemistry.chemical_compound 0302 clinical medicine Cerebrospinal fluid Electroconvulsive therapy Neurogranin cerebrospinal fluid [Sphingolipids]Electroconvulsive Therapy Klotho Glucuronidase Aged 80 and over therapy [Depressive Disorder Major]Neopterin Interleukin Middle Aged Psychiatry and Mental health Treatment Outcome Neuropsychology and Physiological Psychology cerebrospinal fluid [Biomarkers]cerebrospinal fluid [Glucuronidase]Biomarker (medicine)Antidepressant Female Adult medicine.medical_specialty klotho protein Young Adult 03 medical and health sciences Internal medicine mental disorders medicine Humans ddc:610 Klotho Proteins Biological Psychiatry cerebrospinal fluid [Nerve Degeneration]Aged Depressive Disorder Major Sphingolipids business.industry cerebrospinal fluid [Depressive Disorder Major]Immunity Innate 030227 psychiatry chemistry Nerve Degeneration cerebrospinal fluid [Endocannabinoids]business Biomarkers 030217 neurology & neurosurgery Endocannabinoids

description

Background: No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet. Method: Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, β-amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT in patients with depression (n = 12) to identify possible correlations with the clinical antidepressant response to ECT. Results: Correlation with the reduction of the depressive symptoms could be observed especially for markers of neurodegeneration and elements of the innate immune system. Differences for CSF levels of several markers were found between the groups of responders and non-responders at the trend level. Limitations: The sample size is small and the distribution of responders and non-responders is uneven. Conclusions: It is this first study on CSF biomarkers for antidepressant efficacy of ECT warrants further research regarding the mechanism of ECT and personalized antidepressant therapy.

year	journal	country	edition	language
2018-05-18	Neuropsychobiology

https://doi.org/10.1159/000491401